Abstract
Recent interest has focused on the potential role of amylin in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). This 37-amino acid peptide is found in extracellular amyloid deposits in ∼50% of pancreatic islets of patients with NIDDM and has been shown to inhibit skeletal muscle glycogen synthesis in vitro, lmmunocytochemical studies have colocalized amylin and insulin within ß-cell secretory granules in nondiabetic humans, provoking the following questions. Is amylin cosecreted with insulin? Are circulating amylin concentrations higher in patients with NIDDM either before or after food ingestion? To answer these questions, we developed a sensitive and specific immunoassay to measure plasma concentrations of amylin in humans. Use of this assay indicated that, in lean nondiabetic subjects, glucose ingestion resulted in an increase (P < 0.001) in the plasma concentration of amylin (from 2.03 ± 0.22 to 3.78 ± 0.39 pM) and insulin (from 48.3 ± 3.1 to 265 ± 44 pM). There was a significant correlation between the concentrations of insulin and amylin (r = 0.74, P < 0.001) and the increase in insulin and amylin concentration (r = 0.65, P < 0.005). Fasting concentrations of amylin did not differ in diabetic and weight-matched nondiabetic subjects and showed a similar pattern of change after ingestion of a mixed meal. We conclude that amylin is secreted in response to ingestion of either glucose or a mixed meal and circulates at concentrations that do not differ in patients with NIDDM and nondiabetic subjects. It remains to be determined whether amylin at physiological concentrations influences carbohydrate metabolism and if so whether its effects differ in diabetic and nondiabetic humans.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 752-756 |
| Number of pages | 5 |
| Journal | Diabetes |
| Volume | 39 |
| Issue number | 6 |
| State | Published - Jun 1990 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. / Butler, Peter C.; Chou, Joanne; Carter, W. Bradford; Wang, Yeng Nung; Bu, Bing Hong; Chang, Ding; Chang, Jaw Kang; Rizza, Robert A.
In: Diabetes, Vol. 39, No. 6, 06.1990, p. 752-756.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans
AU - Butler, Peter C.
AU - Chou, Joanne
AU - Carter, W. Bradford
AU - Wang, Yeng Nung
AU - Bu, Bing Hong
AU - Chang, Ding
AU - Chang, Jaw Kang
AU - Rizza, Robert A.
PY - 1990/6
Y1 - 1990/6
N2 - Recent interest has focused on the potential role of amylin in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). This 37-amino acid peptide is found in extracellular amyloid deposits in ∼50% of pancreatic islets of patients with NIDDM and has been shown to inhibit skeletal muscle glycogen synthesis in vitro, lmmunocytochemical studies have colocalized amylin and insulin within ß-cell secretory granules in nondiabetic humans, provoking the following questions. Is amylin cosecreted with insulin? Are circulating amylin concentrations higher in patients with NIDDM either before or after food ingestion? To answer these questions, we developed a sensitive and specific immunoassay to measure plasma concentrations of amylin in humans. Use of this assay indicated that, in lean nondiabetic subjects, glucose ingestion resulted in an increase (P < 0.001) in the plasma concentration of amylin (from 2.03 ± 0.22 to 3.78 ± 0.39 pM) and insulin (from 48.3 ± 3.1 to 265 ± 44 pM). There was a significant correlation between the concentrations of insulin and amylin (r = 0.74, P < 0.001) and the increase in insulin and amylin concentration (r = 0.65, P < 0.005). Fasting concentrations of amylin did not differ in diabetic and weight-matched nondiabetic subjects and showed a similar pattern of change after ingestion of a mixed meal. We conclude that amylin is secreted in response to ingestion of either glucose or a mixed meal and circulates at concentrations that do not differ in patients with NIDDM and nondiabetic subjects. It remains to be determined whether amylin at physiological concentrations influences carbohydrate metabolism and if so whether its effects differ in diabetic and nondiabetic humans.
AB - Recent interest has focused on the potential role of amylin in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). This 37-amino acid peptide is found in extracellular amyloid deposits in ∼50% of pancreatic islets of patients with NIDDM and has been shown to inhibit skeletal muscle glycogen synthesis in vitro, lmmunocytochemical studies have colocalized amylin and insulin within ß-cell secretory granules in nondiabetic humans, provoking the following questions. Is amylin cosecreted with insulin? Are circulating amylin concentrations higher in patients with NIDDM either before or after food ingestion? To answer these questions, we developed a sensitive and specific immunoassay to measure plasma concentrations of amylin in humans. Use of this assay indicated that, in lean nondiabetic subjects, glucose ingestion resulted in an increase (P < 0.001) in the plasma concentration of amylin (from 2.03 ± 0.22 to 3.78 ± 0.39 pM) and insulin (from 48.3 ± 3.1 to 265 ± 44 pM). There was a significant correlation between the concentrations of insulin and amylin (r = 0.74, P < 0.001) and the increase in insulin and amylin concentration (r = 0.65, P < 0.005). Fasting concentrations of amylin did not differ in diabetic and weight-matched nondiabetic subjects and showed a similar pattern of change after ingestion of a mixed meal. We conclude that amylin is secreted in response to ingestion of either glucose or a mixed meal and circulates at concentrations that do not differ in patients with NIDDM and nondiabetic subjects. It remains to be determined whether amylin at physiological concentrations influences carbohydrate metabolism and if so whether its effects differ in diabetic and nondiabetic humans.
UR - http://www.scopus.com/inward/record.url?scp=0025287442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025287442&partnerID=8YFLogxK
M3 - Article
C2 - 2189768
AN - SCOPUS:0025287442
VL - 39
SP - 752
EP - 756
JO - Diabetes
JF - Diabetes
SN - 0012-1797
IS - 6
ER -